519 related articles for article (PubMed ID: 15471829)
21. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors.
Weber W; Bartenstein P; Gross MW; Kinzel D; Daschner H; Feldmann HJ; Reidel G; Ziegler SI; Lumenta C; Molls M; Schwaiger M
J Nucl Med; 1997 May; 38(5):802-8. PubMed ID: 9170450
[TBL] [Abstract][Full Text] [Related]
22. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.
Kurland BF; Muzi M; Peterson LM; Doot RK; Wangerin KA; Mankoff DA; Linden HM; Kinahan PE
J Nucl Med; 2016 Feb; 57(2):226-30. PubMed ID: 26493206
[TBL] [Abstract][Full Text] [Related]
23. Comparison of early and delayed FDG PET for evaluation of biliary stricture.
Nishiyama Y; Yamamoto Y; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Ohkawa M
Nucl Med Commun; 2007 Dec; 28(12):914-9. PubMed ID: 18090217
[TBL] [Abstract][Full Text] [Related]
24. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
Conrad GR; Sinha P
Nucl Med Commun; 2003 Nov; 24(11):1129-37. PubMed ID: 14569166
[TBL] [Abstract][Full Text] [Related]
25. 18F alpha-methyl tyrosine PET studies in patients with brain tumors.
Inoue T; Shibasaki T; Oriuchi N; Aoyagi K; Tomiyoshi K; Amano S; Mikuni M; Ida I; Aoki J; Endo K
J Nucl Med; 1999 Mar; 40(3):399-405. PubMed ID: 10086702
[TBL] [Abstract][Full Text] [Related]
26. The comparison of 13N-ammonia and 18F-FDG in the evaluation of untreated gliomas.
Shi X; Liu Y; Zhang X; Yi C; Wang X; Chen Z; Zhang B
Clin Nucl Med; 2013 Jul; 38(7):522-6. PubMed ID: 23698463
[TBL] [Abstract][Full Text] [Related]
27. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer.
Pauleit D; Zimmermann A; Stoffels G; Bauer D; Risse J; Flüss MO; Hamacher K; Coenen HH; Langen KJ
J Nucl Med; 2006 Feb; 47(2):256-61. PubMed ID: 16455631
[TBL] [Abstract][Full Text] [Related]
28. Comparison of effects of 18F-FDG PET-CT and MRI in identifying and grading gliomas.
Song PJ; Lu QY; Li MY; Li X; Shen F
J Biol Regul Homeost Agents; 2016; 30(3):833-838. PubMed ID: 27655507
[TBL] [Abstract][Full Text] [Related]
29. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.
Kim YH; Oh SW; Lim YJ; Park CK; Lee SH; Kang KW; Jung HW; Chang KH
Clin Neurol Neurosurg; 2010 Nov; 112(9):758-65. PubMed ID: 20619531
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model.
Wang HE; Wu SY; Chang CW; Liu RS; Hwang LC; Lee TW; Chen JC; Hwang JJ
Nucl Med Biol; 2005 May; 32(4):367-75. PubMed ID: 15878506
[TBL] [Abstract][Full Text] [Related]
31. 11C-CHO PET in optimization of target volume delineation and treatment regimens in postoperative radiotherapy for brain gliomas.
Li FM; Nie Q; Wang RM; Chang SM; Zhao WR; Zhu Q; Liang YK; Yang P; Zhang J; Jia HW; Fang HH
Nucl Med Biol; 2012 Apr; 39(3):437-42. PubMed ID: 22172386
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors.
Hamada K; Tomita Y; Ueda T; Enomoto K; Kakunaga S; Myoui A; Higuchi I; Yoshikawa H; Hatazawa J
Ann Nucl Med; 2006 Dec; 20(10):671-5. PubMed ID: 17385305
[TBL] [Abstract][Full Text] [Related]
33. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients.
Schöder H; Erdi YE; Chao K; Gonen M; Larson SM; Yeung HW
J Nucl Med; 2004 Apr; 45(4):559-66. PubMed ID: 15073250
[TBL] [Abstract][Full Text] [Related]
34. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine.
Kaschten B; Stevenaert A; Sadzot B; Deprez M; Degueldre C; Del Fiore G; Luxen A; Reznik M
J Nucl Med; 1998 May; 39(5):778-85. PubMed ID: 9591574
[TBL] [Abstract][Full Text] [Related]
35. Prediction of pathology and survival by FDG PET in gliomas.
Padma MV; Said S; Jacobs M; Hwang DR; Dunigan K; Satter M; Christian B; Ruppert J; Bernstein T; Kraus G; Mantil JC
J Neurooncol; 2003 Sep; 64(3):227-37. PubMed ID: 14558598
[TBL] [Abstract][Full Text] [Related]
36. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
37. [Validation of MRI and 18F-FDG-PET coregistration in patients with primary brain tumors].
Ortega-López N; Mendoza-Vásquez RG; Adame-Ocampo G; Alexanderson-Rosas E; Cayetano-Alcaraz AA; Angel-Celis M
Gac Med Mex; 2007; 143(4):309-16. PubMed ID: 17969839
[TBL] [Abstract][Full Text] [Related]
38. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
39. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma.
Lin WY; Tsai SC; Hung GU
Nucl Med Commun; 2005 Apr; 26(4):315-21. PubMed ID: 15753790
[TBL] [Abstract][Full Text] [Related]
40. 18F-FET PET differentiation of ring-enhancing brain lesions.
Floeth FW; Pauleit D; Sabel M; Reifenberger G; Stoffels G; Stummer W; Rommel F; Hamacher K; Langen KJ
J Nucl Med; 2006 May; 47(5):776-82. PubMed ID: 16644747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
